The two long-acting amylin analogues, compared on mechanism, trial data, and development stage — including the authentication caveat nobody else will tell you about.
Both copy amylin, one of the body's natural "I'm full" signals — a completely separate pathway from the GLP-1 drugs. Eloralintide's headline number is bigger (20.1% vs 10.8%), but cagrilintide's program is further along: it's in phase 3, including the CagriSema combination with semaglutide that posted 22.7% in REDEFINE-1. The honest difference that matters most right now isn't efficacy — it's evidence maturity, and our ability to authenticate what you're actually getting.
| Cagrilintide | Eloralintide | |
|---|---|---|
| Mechanism | Long-acting amylin analogue | Amylin analogue (once-weekly) |
| Headline trial | Phase 2, 4.5 mg | Phase 2, 9 mg |
| Mean weight loss | 10.8% at 26 weeks | 20.1% at 48 weeks |
| Development stage | PHASE 3 (incl. CagriSema combo) | PHASE 3 (headline data phase 2) |
| Authentication | Standard batch-matched COA | Sequence cannot be proven by routine HPLC/MS — limitation stated |
| TrueNorth from | C$75 (5 mg) | C$68 (20 mg) |
| View Cagrilintide | View Eloralintide |
Amylin is co-secreted with insulin and signals satiety through the brainstem — a different circuit from the gut-hormone incretins. That's why the field is excited about combinations: hitting two independent fullness pathways at once. REDEFINE-1 (cagrilintide + semaglutide, 22.7% at 68 weeks) is the proof of concept, and it's one of the most watched readouts in obesity medicine.
The practical problem is analytical, not pharmacological. Eloralintide is a 37-amino-acid lipidated peptide — large enough that standard purity and intact-mass checks can't confirm its full sequence. Most sellers won't tell you that. We do, on the product page, because a COA that can't prove identity is a claim, not evidence.
No. Both are long-acting amylin analogues, but they are different molecules from different development programs, at different stages: cagrilintide is in phase 3 (including the CagriSema combination program), while eloralintide's headline data comes from phase 2.
On headline numbers, eloralintide's 20.1% (phase 2, 48 weeks) beats cagrilintide's 10.8% (phase 2, 26 weeks) — but the trials differ in duration, dose, and population, so this is directional, not a ranking. Cagrilintide has the more advanced program overall.
Eloralintide is a 37-amino-acid lipidated peptide (~4.5 kDa). Routine HPLC purity and intact-mass checks cannot prove the full amino-acid sequence of a molecule that complex — so we state the limitation openly instead of presenting a generic COA as proof.
That is exactly what the combination programs are testing: cagrilintide + semaglutide (REDEFINE-1: 22.7% at 68 weeks) is the most advanced amylin + incretin combination in phase 3.
All compounds are sold strictly as laboratory research chemicals — not for human consumption. Trial figures are mean changes in the cited trial populations; see the science guide for context.
